Major histocompatibility complex class I molecule presenting Epstein-Barr virus peptide (MHC class I)

The major histocompatibility complex class I molecule presenting Epstein-Barr virus peptide is a cell-surface glycoprotein complex (typically including a heavy chain, β2-microglobulin, and a bound peptide of 8–10 amino acids) responsible for presenting endogenous antigens—including those derived from EBV proteins such as EBNA1—to CD8^+ T cells. This antigen presentation is essential for the immune system to recognize and eradicate virus-infected or transformed cells[2][3][9]. EBV has evolved proteins (BNLF2a, BGLF5, BILF1) to interfere with this pathway, reducing immune recognition during latent and lytic infection phases[4][5][6]. The presentation of EBV peptides, especially in the context of conserved MHC class I alleles such as HLA-B8, is critical for immunotherapeutic approaches to EBV-associated malignancies and designing vaccines targeting these epitopes[2][8].

Other names

MHC class IHLA class IHLA-B8peptide-MHC class I complex

Immunomodulatory molecules (e.g., viral proteins such as EBV BNLF2a can inhibit peptide loading and thus antigen presentation by MHC class I) Proteasome inhibitors block antigen processing, thereby reducing epitope presentation Experimental small molecules may block viral proteins interfering with MHC class I surface expression